Test Price
2,800 AED✅ Home Collection Available
COG7 Gene Glycosylation Disorder Type 2E Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- ✔Diagnostic Accuracy: 99.9% analytical sensitivity for single nucleotide variants and small indels via ISO-accredited NGS processing.
- ✔Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM.
- ✔Clinical Support: Post-test telephonic consultation with a licensed medical geneticist for result interpretation and family counseling.
- ✔Insurance Assistance: Direct insurance coverage verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This advanced genetic test analyzes the COG7 gene using Next-Generation Sequencing (NGS) to diagnose Glycosylation Disorder Type 2E, a severe congenital disorder of glycosylation causing neurological impairment. The test detects single nucleotide variants (SNVs), small insertions/deletions, and copy number variations (CNVs) with 99.9% analytical sensitivity, enabling precise clinical management and family genetic counseling.
| Feature | Our Test (NGS Panel) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Method | Next-Generation Sequencing (NGS) | Sanger Sequencing (single-amplicon) |
| Genetic Coverage | Full gene analysis: all exons, splice sites, CNV detection | Targeted hotspot exons only, no CNV |
| Diagnostic Sensitivity | >99.9% for SNVs/indels, 95% for CNVs | ~85% (limited region) |
| Turnaround Time | 3–4 Weeks | 2–3 Weeks |
| Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Not guaranteed |
Physician Insight & Safety Protocols
As a Consultant Medical Genetics, I understand the anxiety surrounding genetic testing for a child exhibiting developmental delays and seizures. Early diagnosis of COG7-CDG can guide targeted interventions and prevent unnecessary invasive procedures. Please remember that genetic results must be interpreted in the context of clinical findings; I strongly recommend discussing your plan with a licensed geneticist.
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication and Clinical Context
Do not discontinue any prescribed medication without consulting your doctor. Changing antiepileptic drugs or metabolic supplements can precipitate severe neurological deterioration. This test provides genetic information that should always be interpreted together with full clinical evaluation.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Active febrile illness or bacterial infection within 48 hours of blood draw; recent blood transfusion (less than 3 weeks) may confound genetic analysis; inability to provide valid informed consent (for minors, both parents/guardians must consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- ER Red Flags: Sudden loss of consciousness, uncontrolled seizures lasting more than 5 minutes, or difficulty breathing – seek immediate emergency care by dialing 998 or visiting nearest hospital. Do not delay for test logistics.
Patient FAQ & Clinical Guidance
1. What is the purpose of the COG7 gene NGS test?
The COG7 NGS test identifies disease-causing variants in the COG7 gene responsible for congenital disorder of glycosylation type IIe, providing a molecular diagnosis for affected individuals presenting with neurological and systemic manifestations.
2. How should I prepare my child for the test?
Ensure the child is well-hydrated; fasting is not required. A genetic counseling session to draw a pedigree chart of family members affected with COG7-related glycosylation disorder is mandatory before sample collection.
3. What does a positive result mean for my family?
A positive result confirms a COG7 pathogenic variant, enabling targeted clinical management, recurrence risk counseling (autosomal recessive, 25% recurrence in siblings), and potential inclusion in carrier screening for relatives.
4. What is the turnaround time and how will I receive results?
Turnaround time is 3–4 weeks from sample receipt. Results are delivered electronically via secure patient portal and in a physical report signed by the Consultant Medical Genetics. A telephonic consultation is included.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143. All genetic data handling complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic information is encrypted, stored securely, and never shared without explicit consent.
Clinical & Logistical Metadata
| Test Name | COG7 Gene Glycosylation Disorder Type 2E Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM – 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full gene analysis including CNV detection |
| ICD-10-CM Code | E77.8, E77.9 |
| LOINC Code | 91867-5 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians